197 related articles for article (PubMed ID: 19744131)
1. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).
Pulsipher MA; Wall DA; Grimley M; Goyal RK; Boucher KM; Hankins P; Grupp SA; Bunin N
Br J Haematol; 2009 Dec; 147(5):691-9. PubMed ID: 19744131
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
[TBL] [Abstract][Full Text] [Related]
3. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Pulsipher MA; Langholz B; Wall DA; Schultz KR; Bunin N; Carroll WL; Raetz E; Gardner S; Gastier-Foster JM; Howrie D; Goyal RK; Douglas JG; Borowitz M; Barnes Y; Teachey DT; Taylor C; Grupp SA
Blood; 2014 Mar; 123(13):2017-25. PubMed ID: 24497539
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
5. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
Farag SS; Abu Zaid M; Schwartz JE; Thakrar TC; Blakley AJ; Abonour R; Robertson MJ; Broxmeyer HE; Zhang S
N Engl J Med; 2021 Jan; 384(1):11-19. PubMed ID: 33406328
[TBL] [Abstract][Full Text] [Related]
8. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R; Nakamura R; Palmer JM; Parker P; Shayani S; Nademanee A; Snyder D; Pullarkat V; Kogut N; Rosenthal J; Smith E; Karanes C; O'Donnell M; Krishnan AY; Senitzer D; Forman SJ
Blood; 2010 Feb; 115(5):1098-105. PubMed ID: 19965688
[TBL] [Abstract][Full Text] [Related]
9. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.
Pidala J; Kim J; Jim H; Kharfan-Dabaja MA; Nishihori T; Fernandez HF; Tomblyn M; Perez L; Perkins J; Xu M; Janssen WE; Veerapathran A; Betts BC; Locke FL; Ayala E; Field T; Ochoa L; Alsina M; Anasetti C
Haematologica; 2012 Dec; 97(12):1882-9. PubMed ID: 22689677
[TBL] [Abstract][Full Text] [Related]
13. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch.
Al Malki MM; Gendzekhadze K; Yang D; Mokhtari S; Parker P; Karanes C; Palmer J; Snyder D; Forman SJ; Nademanee A; Nakamura R
Transplantation; 2020 May; 104(5):1070-1080. PubMed ID: 31449184
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
16. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
Sano H; Mochizuki K; Kobayashi S; Ohara Y; Ito M; Waragai T; Takahashi N; Ikeda K; Ohto H; Kikuta A
Int J Hematol; 2018 Jul; 108(1):76-84. PubMed ID: 29508228
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
Armand P; Gannamaneni S; Kim HT; Cutler CS; Ho VT; Koreth J; Alyea EP; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Antin JH
J Clin Oncol; 2008 Dec; 26(35):5767-74. PubMed ID: 19001324
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Aldoss I; Tsai NC; Slovak ML; Palmer J; Alvarnas J; Marcucci G; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1212-1217. PubMed ID: 27044907
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
